| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $148.0M | +2.7% |
| SG&A Expense | $32.9M | -32.7% |
| Operating Income | -$180.9M | +6.3% |
| Pre-tax Income | -$164.5M | +1.8% |
| Income Tax | -$6.2M | -766.2% |
| Net Income | -$158.3M | +6.0% |
| EPS (Basic) | -$1.94 | +3.0% |
| EPS (Diluted) | -$1.94 | +3.0% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $95.7M | +47.9% |
| Current Assets | $311.0M | -32.7% |
| Total Assets | $315.2M | -32.2% |
| Current Liabilities | $39.8M | +113.9% |
| Total Liabilities | $39.8M | +54.2% |
| Stockholders' Equity | $275.4M | -37.2% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$132.0M | +2.6% |
| Investing Cash Flow | $188.8M | +236.5% |
| Financing Cash Flow | -$25.7M | -9742.3% |